Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer

LONDON & PALO ALTO, Calif.--(BUSINESS WIRE)--TRACC Part C trial will use Guardant Reveal ctDNA blood test to evaluate opportunity to reduce unnecessary use of chemotherapy in colorectal cancer

Click to view original post